Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
We have reported separately on a small, Phase II trial of neoadjuvant chemotherapy prior to radical prostatectomy in men with locally advanced, high risk prostate cancer. Other reports today address: Prostate cancer detection and treatment in China The effectiveness of preoperative nomograms in men diagnosed with PSA levels < 2.5 ng/ml Body mass index and [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Leave a Comment »
A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity.
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", Abraxane, locally advanced, neoadjuvant, paclitaxel | Leave a Comment »
A study from investigators at M. D. Anderson Cancer Center has attempted to assess the likelihood of total eradication of prostate cancer in men with prostate cancer that is found in only one lobe of the prostate and who would qualify for subtotal prostate ablation with controlled thermal energy using such techniques as cryoablation or [...]
Filed under: Management, Treatment | Tagged: eligibility, focal therapy, potential | 1 Comment »
There are six new reports in today’s news, of which the most immediately important would seem to be: How men manage their “fear” while on active surveillance “Cancer anxiety” and early use of hormonal therapy Approval for a Phase III clinical trial of MDV3100
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active suirveillance, cancer anxiety, denosumab, forkhead transcription factors, FOX factors, hormone therapy, MDV3100, testosterone | Leave a Comment »
We thought it might be wise to make sure that readers of The “New” Prostate Cancer InfoLink didn’t just hear what we thought about today’s two NEJM articles, but also got a cross-section of perspectives from others. Where relevant we have taken the liberty of giving our opinion on the articles we think you might [...]
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, screening | 1 Comment »
As we have already, albeit briefly, reported, two “major” papers were published in the New England Journal of Medicine today, and they both were designed to address the appropriateness of mass screening for prostate cancer — among men over the age of 55 years in the USA and over 50 years in Europe respectively. We [...]
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, randomized trial, screening | 11 Comments »
As at least some readers will be aware, data from two major screening studies were published today in the New England Journal of Medicine. The “New” Prostate Cancer InfoLink wishes to read these studies with great care before commenting on the data. For those who wish to read the studies for themselves, here are the [...]
Filed under: Diagnosis, Risk | Tagged: screening | 1 Comment »
Today we cover reports on: The incidence of prostate cancer among older HIV-positive men ARTS and the potential of dutasteride in treatment of patients with biochemical recurrence PET scans and their use in detection of biochemical recurrence Chemotherapy in treatment of prostate cancer
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: ARTS, chemotherapy, dutasteride, HIV, incidence, PET scan | Leave a Comment »
… comes information that Don Imus, the radio commentator, and David Prowse, best known for his portrayal of mega-villain Darth Vader in the Star Wars movies, have both been diagnosed with prostate cancer. Never short of an opinion on things that matter to him, Imus is quoted as stating that, “I think it was all [...]
Filed under: Living with Prostate Cancer | Tagged: David Prowse, Don Imus | 6 Comments »
In December 2008 we reported the results of the effects of endocrine treatment with or without radiotherapy on mortality, as studied in the SPCG-7/SFUO-3 trial. In patients who received both treatments, prostate cancer-specific mortality was halved, relative to that in patients who received endocrine treatment alone. The same group of researchers have now published data [...]
Filed under: Management, Treatment | Tagged: endocrine therapy, outcome, quality of life, radiotherapy | Leave a Comment »
One would normally expect Susan B. Komen for the Cure to be an ardent supporter of cancer screening — in the interests of women at risk for breast cancer … but they are the providers of an article just published in Readers Digest entitled, “Cancer Screening: Doing More Harm than Good?” What is going on?
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, risk, screening | 1 Comment »
On February 20 we noted media reports that a study from Johns Hopkins was suggesting that routine PSA tests offer no benefit to many men aged between 75 and 80 years of age.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: age, PSA | Leave a Comment »
There are four reports in today’s news of any real interest to the patient community. They deal with: The progress of the Prostate Cancer Clinical Trials Consortium Antiandrogens in prevention of prostate cancer (maybe) Disseminated tumor cells and prostate cancer progression Oral fenretinide in treatment of biochemical relapse after first-line therapy
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: antiadrogens, disseminated tumor cells, fenretinine, Prevention, Prostate Cancer Clinical Trials Consortium | Leave a Comment »
A report has just been published of a multi-center retrospective evaluation of the actuarial rates and predictors of remaining on active surveillance, the incidence of cancer progression, and the pathological findings of delayed radical prostatectomy.
Filed under: Management, Risk, Treatment | Tagged: active surveillance, outcomes | Leave a Comment »
We have added information about three more recent studies for your weekend reading, dealing with: Soy, diet, and prostate cancer prevention Outcomes of bladder neck preservation during radical prostatectomy A predictive model for chemotherapy outcomes in HRPC patients
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: bladder neck preservation, chemotherapy, diet, hormone-refractory prostate cancer, nomogram, outcome, Prevention, risk, soy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site